CIN-107
Sponsors
CinCor Pharma, Inc., AstraZeneca
Conditions
Chronic Kidney DiseasesHypertensionResistant HypertensionUncontrolled Hypertension
Phase 1
Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function
CompletedNCT05470725
Start: 2021-01-12End: 2021-04-30Updated: 2023-08-14
Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects
CompletedNCT05500820
Start: 2019-12-19End: 2020-04-03Updated: 2023-08-14
Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects
CompletedNCT05526690
Start: 2020-10-28End: 2020-12-12Updated: 2023-08-14
Phase 2
A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
CompletedNCT04519658
Start: 2020-10-12End: 2022-06-14Updated: 2023-07-24
A Study of CIN-107 in Patients With Uncontrolled Hypertension
CompletedNCT05137002
Start: 2021-12-07End: 2022-10-10Updated: 2023-08-01
A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
CompletedNCT05432167
Start: 2022-04-29End: 2024-05-02Updated: 2025-05-20
Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124
CompletedNCT05459688
Start: 2022-04-06End: 2023-11-07Updated: 2024-12-16